An act to amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
HOUSE REPORTS: No. 114-41, Pt. 1 (Comm. on Energy and Commerce). CONGRESSIONAL RECORD, Vol. 161 (2015): Mar. 16, considered and passed House. Oct. 26, considered and passed Senate, amended. Nov. 16, House concurred in Senate amendment.
Document Citations
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
Office of the Federal Register, National Archives and Records Administration. "Public Law 114 - 89 - Improving Regulatory Transparency for New Medical Therapies Act". Government. U.S. Government Publishing Office, November 25, 2015. https://www.govinfo.gov/app/details/PLAW-114publ89
APA
Office of the Federal Register, National Archives and Records Administration. (2015, November 25). Public Law 114 - 89 - Improving Regulatory Transparency for New Medical Therapies Act. [Government]. U.S. Government Publishing Office. https://www.govinfo.gov/app/details/PLAW-114publ89
MLA
Office of the Federal Register, National Archives and Records Administration. Public Law 114 - 89 - Improving Regulatory Transparency for New Medical Therapies Act. U.S. Government Publishing Office, (25 Nov 2015), https://www.govinfo.gov/app/details/PLAW-114publ89
Bluebook
Improving Regulatory Transparency for New Medical Therapies Act, Pub. L. No. 114-89 (2015), https://www.govinfo.gov/app/details/PLAW-114publ89
